Navigation Links
Imprimis Pharmaceuticals, Inc. to Present at the National Investment Banking Association (NIBA) Conference June 18th in New York City
Date:6/14/2013

SAN DIEGO, June 14, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), which is focused on the commercialization of compounded drug formulations, today announced CEO Mark L. Baum will present at the National Investment Banking Association (NIBA) conference, set for June 17-19 in New York City.  The Imprimis presentation is scheduled for June 18th.

About Imprimis Pharmaceuticals, Inc. Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a specialty pharmaceutical company focused on the commercial development of compounded drug formulations. Through its exclusive strategic relationship with Professional Compounding Centers of America (PCCA), the largest compounding pharmacy organization in North America, Imprimis expects to use its proprietary Accudel drug delivery technologies, as well as proprietary drug formulations for new indications and market data obtained through PCCA, to identify and pursue pharmaceutical development opportunities where there is a significant unmet medical need utilizing the FDA 505(b)(2) regulatory pathway. Imprimis' most near term drug candidate, Impracor, is a Phase III product candidate that utilizes the Accudel topical cream formulation to deliver the active drug ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), through the skin directly into the underlying tissues where the drug exerts its localized anti-inflammatory and analgesic effects. For more information, visit http://imprimispharma.com/.  

About NIBA The National Investment Banking Association (NIBA) is the only not-for-profit association for national, regional and independent broker dealers, investment banking firms, investment advisors, and related capital market service providers.  Its member firms: are responsible for 90 percent of all IPO's under $20 million; have successfully completed more than 1,000 equity offerings; have raised over $10 billion in new capital for emerging growth companies; represent more than 8,800 registered representatives; have more than $76 billion in assets under management; and represent more than 60 key industry services.  For more information, visit http://nibanet.org/.

Contact: Josh Berg
Imprimis Pharmaceuticals, Inc.
(858) 704 4041


'/>"/>
SOURCE Imprimis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Stephen G. Austin, CPA Joins Imprimis Pharmaceuticals Board Of Directors
2. Dr. Gerald Yakatan Joins Imprimis Pharmaceuticals Science and Regulatory Advisory Board
3. Imprimis Pharmaceuticals Signs Agreement With DPT Labs For Clinical Supplies In Advance Of Planned Phase 3 Studies For Its Ketoprofen-Based Topical Anti-Inflammatory Drug
4. Imprimis Names Two Experts To Its Science And Regulatory Board
5. Imprimis to Begin New Study of Its Topical Analgesic Drug
6. Imprimis Pharmaceuticals Announces Pricing of Public Offering of 1,840,000 Shares of Common Stock
7. Imprimis Announces Successful Results from its Pharmacokinetic Study for its Impracor Topical NSAID
8. Imprimis Announces Key Leadership Appointments
9. Imprimis Pharmaceuticals Out Licenses Its Proprietary IP to resolutionMD for Cosmeceutical Products
10. Imprimis Pharmaceuticals Announces Underwriter Exercise of Over-Allotment Option
11. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... HILLS, Calif. , June 20, 2017 SkylineDx ... the use of MMprofiler with SKY92, the company,s prognostic ... In a poster presentation at the 22 nd ... Madrid, Spain , SkylineDx researchers will demonstrate ... patients. In a separate e-poster presentation ...
(Date:6/19/2017)... Pa. , June 19, 2017  Researchers from ... today that they will host a live, complimentary webinar ... from the benchtop to the real world" on Wednesday ... EDT. This webinar will feature interviews ... rare look into the manipulation techniques abusers use to ...
(Date:6/16/2017)... BOSTON , June 16, 2017  Exactly 50 years ... kicked off what later became known as the San Francisco ... www.northernlight.com ) is unveiling two radical innovations in strategic market ... summer.  This announcement marks the beginning of Northern Light,s "Summer ... ...
Breaking Medicine Technology:
(Date:6/28/2017)... , ... June 28, 2017 , ... ... is pleased to announce that a two year study conducted by the University ... Creek zeolite was successful in remediating potash brine-impacted groundwater. As a part of ...
(Date:6/28/2017)... , ... June 28, 2017 , ... ... firm servicing communities throughout the greater Cincinnati metropolitan area, is teaming up with ... lodgings for families with children receiving treatment in nearby hospitals. , Ronald McDonald ...
(Date:6/27/2017)... ... June 27, 2017 , ... Harbour , a ... assets on the Ethereum blockchain, has released their technical specifications . , 2017 ... has been little systematic approach for determining which offerings will garner the greatest ROI. ...
(Date:6/27/2017)... ... June 27, 2017 , ... From June 20-22, EarQ and Widex ... Syracuse, New York, where EarQ is headquartered. , Together, the organizations educate hearing ... today’s savvy consumer, and the latest in hearing technology. At the event, EarQ ...
(Date:6/27/2017)... ... June 27, 2017 , ... PR News is looking ... studies guidebook. This guidebook offers an excellent branding and exposure opportunity for the ... studies and how-to’s that fall into the following categories:, , ...
Breaking Medicine News(10 mins):